Serenex gain $31M in fourth round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Serenex
|
$31M
|
Cornell Capital Partners, Pearl Street Ventures, MC Life Science Ventures and Pac-Link Bio Venture Capital |
The money will be used to fuel the clinical development of two cancer products--SNX-1012 and SNX-5422--as well as its work on Heat Shock Protein 90 (Hsp90) inhibitors. |
|
BioVex
|
$22M
|
New Science Ventures |
BioVex is working to develop new therapies for cancer and infectious diseases. |
|
Serentis
|
$20.6M
|
MVM Life Science Partners, Apposite Capital and Novo A/S |
The money is being earmarked to push its lead candidates into proof of principle trials and provide the buying power to in-license new drug candidates. |
|
Koronis Pharmaceuticals
|
$20M
|
Pacific Horizon Ventures Asset Management Company |
The money will be used to advance its antiviral therapeutics based on Viral Decay Acceleration. |
|
Diatos
|
$12.8M
|
GIMV Credit Agricole Private Equity, InterWest Partners, Innoven Partenaires, Sofinnova Partners and Biotech Fund Flanders |
The new injection of funding will allow Diatos to further develop its leading clinical products. |
|
Company Name
|
$8.7M
|
Safeguard Scientifics |
Cellumen will use the funds to complete its management team, further develop its product catalog, continue its CSB platform development, and commercialize its cellular models of disease and cytotoxicity profiling services and products. |
|
CODA Genomics
|
$7M
|
OVP Venture Partners |
CODA develops protein production technology. |